Navigation Links
Drug Firms Competing to Produce Cheap and Effective bird flu vaccine

With GlaxoSmithKline claiming to be able to produce far more doses of bird flu vaccine than its rivals the battle ground has been set to to create a cheap// but effective human bird flu vaccine.

GSK is hoping to produce large quantities of the vaccine to challenge the H5N1 bird flu by next year following encouraging results in trials. Although most products are still in development many companies are already vying with each other to interest governments in their products. GSK's rivals Baxter and Chiron have already supplied Britain with 3.5m doses in £33m contracts, to protect health and other frontline workers in the event of a pandemic.

According to GSK it will use lower doses of active ingredient in the vaccine because it has a better adjuvant.

GSK is using an inactivated strain of H5N1 that was isolated in Indonesia last year. Companies are using the H5N1 strains that have been found over the last three years in south Asia. That is where the greatest threat exists, of avian flu in birds, changing to avian flu in humans followed by new pandemic strains.

10 countries have reported a total of 232 cases of confirmed avian flu so far with 134 people dying.

Indonesia, has reported 42 deaths of 54 who were infected with the disease. Fears exist of the virus mutating as the disease spreads within families or close-knit communities. Although it is still not certain that any vaccine would be effective against H5N1 in humans against new pandemic strains it is expected to provide some immunity.

Nevertheless, this new generation of vaccines is better than the antivirals, large amounts of which are already used against traditional flu and are being stockpiled round the world as emergency treatments for symptoms of avian and pandemic flu too. A combination of all these would help to buy more time to develop vaccines against any pandemic strain, but this could probably take months. For now the government has placed ' sleeping contracts' for 120m doses of pandemic vaccine to ensure access to such a vaccine.

GSK conducted a trial run of the vaccine on some 400 adults in Belgium. It claimed that the vaccine had prompted a strong response in 80% of people tested. According to JP Garnier, its chief executive officer, said: 'There is still more work to be done, but the validation of our approach provides us with confidence to continue.'

If all goes well the vaccine would be put to medicine regulators in the coming months. Each shot of the vaccine is expected to cost around £4.In the meanwhile Glaxo is negotiating with groups such as the Bill and Melinda Gates Foundation and the Global Fund about funding it for poor countries.

The Department of Health said, 'We welcome developments which will help to increase vaccine capacity and will build these developments into our pandemic influenza planning.'


Related medicine news :

1. Firms Told To Employ Those With Aspergers Syndrome
2. Drug Firms To Produce Single Pill AIDS Treatment
3. 12 Chinese Firms Appeal Against Court Ruling On Viagra
4. Drug Firms Meet Annan, Pledge on AIDS Medicines
5. US, India Firms Develop New Cure for Black Fever
6. Chemical Firms are Secretly Paying Scientists
7. Supreme Court Seeks Replies From Cola Firms
8. Males Adapt To Battle With Competing Sperm
9. ‘Protein’ Produced By Overstressed Heart Muscle a Strong Indicator Of Heart Diseae
10. Exposure to Pesticides in Schools Produces Illnesses Among Employees, Students
11. World’s First Nerve Stem Cells Produced
Post Your Comments:

(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to ... “patient engagement.” The patient is doing more than filling out a survey; in many ... is an increasing emphasis in health care and research on the importance of active ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
(Date:9/19/2017)... ANN ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical ... the precise destruction of targeted tissues, announced three leadership team developments today:   ... Josh Stopek, PhD ... ... Veteran medical device executive ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , the ... chains, has published the first annual edition of its Global CSR Risk ... 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly ... ... Performance Index ...
Breaking Medicine Technology: